FDA plans ultra-fast review of three psychedelic drugs following Trump directive
By MATTHEW PERRONE WASHINGTON (AP) — The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest step by the Trump administration toward possible approval of the experimental treatments. President…